News
Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"
Novo Nordisk today announced the filing of 14 new lawsuits to safeguard patients from unsafe and unapproved compounded drugs claiming to contain "semaglutide." The defendants named in these lawsuits employ tactics that deceive patients into believing compounded products have been reviewed and approved by FDA or have equivalent safety or effectiveness as Novo Nordisk's approved semaglutide medicines.
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...
President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...
MarketBeat on MSN5h
Novo Nordisk Stock Sinks—But Is a Bottom Finally In?Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...
6h
Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...
Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback